BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25575440)

  • 1. Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials.
    Su W; Lai Z; Wu F; Lin Y; Mo Y; Yang Z; Wu J
    Med Oncol; 2015 Feb; 32(2):481. PubMed ID: 25575440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis.
    Fan XL; Cai GP; Zhu LL; Ding GM
    Drug Des Devel Ther; 2015; 9():5925-32. PubMed ID: 26604690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
    Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
    Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
    Yu W; Tang L; Lin F; Yao Y; Shen Z
    Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
    J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoadjuvant treatment in osteosarcomas].
    Kalifa C; Brugières L; Le Deley MC
    Bull Cancer; 2006 Nov; 93(11):1115-20. PubMed ID: 17145581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
    Bacci G; Ferrari S; Longhi A; Forni C; Bertoni F; Fabbri N; Zavatta M; Versari M
    J Chemother; 2001 Feb; 13(1):93-9. PubMed ID: 11233808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
    Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
    J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
    Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
    J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas.
    Basaran M; Bavbek ES; Saglam S; Eralp L; Sakar B; Atalar AC; Bilgic B; Ozger H; Onat H
    Oncology; 2007; 72(3-4):255-60. PubMed ID: 18185020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial.
    Meyer WH; Pratt CB; Poquette CA; Rao BN; Parham DM; Marina NM; Pappo AS; Mahmoud HH; Jenkins JJ; Harper J; Neel M; Fletcher BD
    J Clin Oncol; 2001 Jan; 19(1):171-82. PubMed ID: 11134210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999.
    Bacci G; Ferrari S; Mercuri M; Longhi A; Fabbri N; Galletti S; Forni C; Balladelli A; Serra M; Picci P
    Acta Orthop; 2007 Jun; 78(3):377-84. PubMed ID: 17611853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
    Lin F; Wang Q; Yu W; Tang L; Zheng S; Sun Y; Shen Z; Yao Y; Dong Y
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):270-5. PubMed ID: 21884438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
    Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
    Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.